SHAREHOLDER ALERT – The Law Offices of Vincent Wong Investigates the Board of Directors of LipoScience, Inc. in Connection With the Sale of the Company to LabCorp – LPDX – MarketWatch
Under the terms of the transaction, LipoScience shareholders will receive $5.25 in cash for each share of LipoScience stock they own. The investigation concerns whether the Board of LipoScience breached their fiduciary duty to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether LabCorp is underpaying for LipoScience shares.
The SEC – like the FCC, EPA, FDA and others – is an industry-captured agency, responsive only to the whining wants of the 1%, not the pressing needs of the 99%.
I formally requested that the SEC deny LabCorp’s acquisition of Orchid Cellmark for two reasons: 1) within LabCorp’s knowledge, Orchid Cellmark was playing games related to the receipt of evidence in suspect condition from Judge W. David Dugan’s Brevard County, Florida court in William Dillon and Gary Bennett’s homicide trials (2008 and 2010, respectively) that were related by the perjured testimony of charlatan dog handler John Preston; and 2) it’s patently obvious that a monopolized, non-competitive DNA test market slows justice to a standstill and allows criminals to remain criminals … despite disbursement of big, big federal bucks to clear up DNA backlogs, the backlogs remain, allowing serial rapists and serial killers to find additional victims.
That our federal regulatory agencies are making monsters instead of slaying them isn’t something we can let our legislators continue to be oh-so-profitably on board with.
If your legislators are sold-out, boot ’em out in November.